Company: MLSS
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001493152-25-022276
Chunk: 109

Company: MILESTONE SCIENTIFIC INC.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 2
Chunk 109
---
 Operations for 2025 and 2024 were as follows: 

    2025  
    2024  
    Change 
  
    Dental 
    $1,328,199  
    $1,526,020  
    $(197,821)
  
    Medical 
     (1,121,237) 
     (1,349,811) 
     228,574 
  
    Corporate 
     (4,823,917) 
     (4,890,879) 
     66,962 
  
    Total loss from operations 
    $(4,616,955) 
    $(4,714,670) 
    $97,715 

The loss from operations for the nine months ended September 30, 2025,
was approximately $4.6 million, compared to $4.7 million for the same period in 2024, representing an improvement of approximately $98,000,
or 2%. The modest improvement primarily reflects lower research and development (R&D) expenses during the period, partially offset
by slightly higher consulting, professional, and regulatory costs within selling, general, and administrative (SG&A) expenses.

Management remains focused on further improving operating results through
disciplined expense management, cost optimization initiatives, and the continued expansion of higher-margin product sales across both
the dental and medical segments

Liquidity and Capital Resources

Cash Flows 

The following table summarizes our sources and uses of cash for the nine
months ended:

    Cash flow:
     
     September 30, 2025

     September 30, 2024

    Change

    Net cash used in operating activities
     
    $
    (2,690,498
    )
     
    $
    (1,408,387
    )
     
    $
    (1,282,111
    )
  
    Net cash (used in) provided by investing activities

    (12,008
    )

    2,969,977

    (2,981,985
    )
  
    Net cash provided by financing activities

    789,749

    236,294

    553,455

    $
    (1,912,757
    )
     
    $
    1,797,884

    $
    (3,710,641
    )

Operating Activities

Net cash used in operating activities increased by approximately $1.3